Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study.
Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH 7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent.
Serretta
V
V
Department of Urology, Civic Hospital Benfratelli, Palermo, Italy.
Piazza
B
B
Pavone
C
C
Piazza
S
S
Pavone-Macaluso
M
M
D000283:Administration, Intravesical; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha